Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.

被引：23
|
作者：
Hong, David S.
Shen, Lin
van Tilburg, Cornelis Martinus
Tan, Daniel Shao-Weng
Kummar, Shivaani
Lin, Jessica Jiyeong
Doz, Francois P.
McDermott, Raymond S.
Albert, Catherine M.
Berlin, Jordan
Bielack, Stefan S.
Lassen, Ulrik Niels
Tahara, Makoto
Norenberg, Ricarda
Shurshalina, Anna
Fellous, Marc Mardoche
Nogai, Hendrik
Xu, Rui-hua
Laetsch, Theodore Willis
Drilon, Alexander E.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Beijing, Peoples R China
[3] Heidelberg Univ Hosp, Hopp Childrens Canc Ctr Heidelberg KiTZ, Heidelberg, Germany
[4] German Canc Res Ctr, Heidelberg, Germany
[5] Natl Canc Ctr Singapore, Singapore, Singapore
[6] OHSU, Knight Canc Inst, Portland, OR USA
[7] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[8] Harvard Med Sch, Boston, MA 02115 USA
[9] Inst Curie, Paris, France
[10] Univ Paris, Paris, France
[11] St Vincents Univ Hosp, Dublin, Ireland
[12] Canc Trials Ireland, Dublin, Ireland
[13] Seattle Childrens Hosp, Seattle, WA USA
[14] Univ Washington, Sch Med, Seattle, WA USA
[15] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[16] Klinikum Stuttgart Olgahosp, Stuttgart, Germany
[17] Rigshosp, Dept Oncol, Copenhagen, Denmark
[18] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[19] Chrestos Concept GmbH & Co KG, Essen, Germany
[20] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[21] Bayer HealthCare Pharmaceut Inc, Basel, Switzerland
[22] Bayer AG, Wuppertal, Germany
[23] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[24] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[25] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[26] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3108
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3108
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
    Moreno, V.
    Lin, J. J.
    Tan, D. S. W.
    Kummar, S.
    Dai, M. -S.
    Lassen, U. N.
    Leyvraz, S.
    Liu, Y.
    Patel, J. D.
    Rosen, L.
    Solomon, B.
    Yachnin, J.
    Norenberg, R.
    Fellous, M.
    Mussi, C. E.
    Shen, L.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S473 - S474
  • [42] Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
    Hong, D. S.
    Tahara, M.
    Baik, C.
    Bauman, J. R.
    Gilbert, J.
    Brose, M. S.
    Grilley-Olson, J. E.
    Patil, T.
    McDermott, R.
    Raez, L. E.
    Johnson, J. M.
    Shen, L.
    Norenberg, R.
    Dima, L.
    Mussi, C.
    Le, X.
    Drilon, A. E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S847 - S848
  • [43] Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
    Lassen, U. N.
    Albert, C. M.
    Kummar, S.
    van Tilburg, C. M.
    Dubois, S. G.
    Geoerger, B.
    Mascarenhas, L.
    Federman, N.
    Schilder, R. J.
    Doz, F.
    Berlin, J. D.
    Oh, D-Y.
    Bielack, S. S.
    McDermott, R.
    Tan, D. S.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Drilon, A.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2018, 29 : 133 - 133
  • [44] Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
    Tan, D. S. W.
    Lassen, U. N.
    Albert, C. M.
    Kummar, S.
    van Tilburg, C.
    Dubois, S. G.
    Geoerger, B.
    Mascarenhas, L.
    Federman, N.
    Basu-Mallick, A.
    Doz, F.
    Berlin, J. D.
    Oh, D-Y.
    Bielack, S.
    McDermott, R.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Drilon, A.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
    Shen, L.
    Hong, D. S.
    Tahara, M.
    Baik, C. S.
    Bauman, J. R.
    Gilbert, J.
    Brose, M. S.
    Grilley-Olson, J. E.
    Patil, T.
    McDermott, R. S.
    Raez, L. E.
    Johnson, J. M.
    Norenberg, R.
    Dima, L.
    Mussi, C. E.
    Le, X.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S1521 - S1522
  • [46] Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
    Waguespack, Steven G.
    Drilon, Alexander
    Lin, Jessica J.
    Brose, Marcia S.
    McDermott, Ray
    Almubarak, Mohammed
    Bauman, Jessica
    Casanova, Michela
    Krishnamurthy, Anuradha
    Kummar, Shivaani
    Leyvraz, Serge
    Oh, Do-Youn
    Park, Keunchil
    Sohal, Davendra
    Sherman, Eric
    Norenberg, Ricarda
    Silvertown, Josh D.
    Brega, Nicoletta
    Hong, David S.
    Cabanillas, Maria E.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 186 (06) : 631 - 643
  • [47] Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
    Blattmann, C.
    Albert, C. M.
    Kummar, S.
    van Tilburg, C. M.
    Dubois, S. G.
    Geoerger, B.
    Mascarenhas, L.
    Federman, N.
    Schilder, R. J.
    Doz, F.
    Berlin, J. D.
    Oh, D. -Y.
    Bielack, S. S.
    McDermott, R.
    Tan, D. S.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Drilon, A.
    Hong, D. S.
    Lassen, U. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 27 - 27
  • [48] Efficacy of larotrectinib in TRK fusion cancer in adults and children
    Blattmann, C.
    Drilon, A.
    Laetsch, T. W.
    Kummar, S.
    DuBois, S. G.
    Lassen, U. N.
    Demetri, G. D.
    Nathenson, M.
    Doebele, R. C.
    Farago, A. F.
    Pappo, A. S.
    Turpin, B.
    Dowlati, A.
    Brose, M. S.
    Mascarenhas, L.
    Federman, N.
    Berlin, J.
    El-Deiry, W. S.
    Baik, C.
    Deeken, J.
    Boni, V.
    Nagasubramanian, R.
    Taylor, M.
    Rudzinski, E. R.
    Meric-Bernstam, F.
    Sohal, D. P. S.
    Ma, P. C.
    Raez, L. E.
    Hechtman, J. F.
    Benayed, R.
    Ladanyi, M.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Hawkins, D. S.
    Hong, D. S.
    Hyman, D. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 154 - 155
  • [49] Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
    Drilon, A.
    Shen, L.
    van Tilburg, C.
    Doz, F.
    Tan, D. S. W.
    Lin, J. J.
    Kummar, S.
    Lassen, U. N.
    McDermott, R. S.
    Dierselhuis, M. P.
    Albert, C. M.
    Nagasubramanian, R.
    Watt, T.
    Patil, T.
    Burcoveanu, D-I.
    Norenberg, R.
    Brega, N.
    Laetsch, T. W.
    Xu, R-H.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S470 - S470
  • [50] Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer
    Drilon, A.
    Lin, J.
    Lassen, U.
    Leyvraz, S.
    Liu, Y.
    Patel, J.
    Rosen, L.
    Solomon, B.
    Norenberg, R.
    Dima, L.
    Brega, N.
    Shen, L.
    Moreno, V.
    Kummar, S.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1125 - S1126
12345